
Reset all filters
01 1Promacta
02 5Promacta/Revolade
03 5Revolade/Promacta
Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,738
2019 Revenue in Millions : 1,416
Growth (%) : 23
Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,016
2020 Revenue in Millions : 1,738
Growth (%) : 16
Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 2,088
2021 Revenue in Millions : 2,016
Growth (%) : 4
Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,269
2022 Revenue in Millions : 2,088
Growth (%) : 9
Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 2,216
2023 Revenue in Millions : 2,269
Growth (%) : -2
EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 24.20%
2013 Revenue in Millions :
Growth (%) :
EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 402
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 635
2015 Revenue in Millions : 402
Growth (%) : 58
EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 867
2016 Revenue in Millions : 635
Growth (%) : 37
EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,174
2017 Revenue in Millions : 867
Growth (%) : 35%